GlassScriptPhysician profile
Nathan R Koscuk
NPI 1326809237
$5,223.50
in general payments reported to CMS, 2019-2025
20 companies · $2,810 in 2025
The $2,810 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,414 · 2025: $2,810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,108 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,108.47 |
| Education | $115.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $913.53 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $761.55 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $733.43 | 2024-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $552.85 | 2024-2025 | Xifaxan |
| Ardelyx, INC. | $368.08 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $281.74 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $262.23 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $248.49 | 2024-2025 | Dupixent |
| Genzyme Corporation | $214.41 | 2024-2025 | |
| Madrigal Pharmaceuticals | $192.63 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $149.48 | 2024-2025 | Vegzelma, Zymfentra |
| Pfizer INC. | $139.20 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $121.14 | 2024-2025 | Rebyota, Clenpiq |
| Ironwood Pharmaceuticals, INC | $84.83 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $59.88 | 2025 | Iqirvo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $57.41 | 2024-2025 | Suflave, Sutab |
| Daiichi Sankyo INC. | $28.76 | 2025 | Enhertu |
| Novo Nordisk INC | $23.09 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.29 | 2024 | Cyltezo |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Koscuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.